Longevity Science: The 12 Hallmarks of Aging and the Emerging Intervention Stack

"Aging is the greatest risk factor for every major disease — cancer, cardiovascular disease, neurodegeneration, metabolic disease. You cannot cure the diseases without addressing the process that generates them." — Zoirah Division Research Brief, Q2 2026

00. Transmission Header

CLASSIFICATION : Tresslers Group Intelligence // Zoirah Division
DOMAIN         : Longevity Science / Geroscience / Hallmarks of Aging / Intervention Biology
STATUS         : Active Intelligence — Scientific and Investment
DATE           : 2026.05.10
FRAMEWORK REF  : López-Otín et al., Cell 2023 — 12 Hallmarks of Aging (updated from 9 in 2013)
CLINICAL REFS  : TAME trial (metformin) — ongoing; PEARL trial (rapamycin) — ongoing
COMPANIES      : Altos Labs (~$3B committed); Calico (Google/Alphabet); Unity Biotechnology; BioAge Labs
ALERT LEVEL    : High — Longevity science at inflection; first clinical evidence accumulating

The field that studies aging has, until recently, operated on a framing that classified aging as an inevitable background condition rather than a tractable biological process. The dominant medical paradigm treated diseases of aging — cancer, Alzheimer's, cardiovascular disease, type 2 diabetes — as separate conditions requiring separate treatments, while aging itself was not a therapeutic target.

That framing is being systematically replaced.

The replacement is driven by a scientific consensus that has accumulated over 30 years: aging is not a random deterioration but a set of specific, measurable, interconnected biological processes — the hallmarks of aging — each of which is, in principle, targetable by molecular interventions. If you can slow, halt, or reverse these hallmark processes, you extend healthspan — the period of healthy, functional life — and almost certainly lifespan as well.

The translation of this science into clinical reality is still in early innings. But the scientific framework is now rigorous enough, the animal data compelling enough, and the investment capital committed enough, that longevity science has moved from gerontology backwater to one of the most competitive fields in biomedical research.

01. The 12 Hallmarks of Aging — The Scientific Framework

The original 9 hallmarks (López-Otín et al., Cell, 2013) established the canonical framework for understanding aging as a biological process with specific, measurable characteristics. In 2023, the same group published an update in Cell expanding to 12 hallmarks, adding three new ones and reorganizing the existing framework.

Rendering diagram...

The three new hallmarks (2023 update):

1. ▸

   Disabled Macroautophagy: Autophagy is the cell's mechanism for breaking down and recycling damaged proteins and organelles — the cellular equivalent of a waste management system. Declining autophagy with age allows damaged cellular components to accumulate, contributing to proteotoxicity, organelle dysfunction, and cancer risk. mTOR inhibition (rapamycin's primary mechanism) upregulates autophagy — one reason rapamycin's effects on aging may be broader than simple nutrient-sensing modulation.

2. ▸

   Chronic Inflammation ("Inflammaging"): Chronic, low-grade, systemic inflammation that increases with age even in the absence of acute infection or injury. Inflammaging is driven by multiple aging hallmarks (senescent cells secreting pro-inflammatory SASP factors, gut dysbiosis, mitochondrial damage-associated molecular patterns) and drives virtually every age-related disease. It is now recognized as both a consequence and a driver of the aging process.

3. ▸

   Dysbiosis: Alterations in the gut microbiome — the community of 38 trillion microorganisms living in the human gut — that occur with aging. These changes affect immune system regulation, metabolic function, nutrient absorption, and brain health via the gut-brain axis. Dysbiosis links aging to inflammation, metabolic disease, and cognitive decline through mechanisms that were not well understood a decade ago.

02. The Intervention Landscape — Current Evidence

Rapamycin — The Benchmark Compound:

Rapamycin (sirolimus) is the most rigorously validated longevity-extending compound across diverse model organisms. Its mechanism:

• ▸Target: mTORC1 (mechanistic Target of Rapamycin Complex 1) — the master nutrient-sensing kinase that regulates cell growth, protein synthesis, and autophagy
• ▸Effect: Inhibiting mTORC1 mimics caloric restriction signaling — cells shift from growth mode to maintenance/repair mode, enhancing autophagy and reducing anabolic processes

Lifespan extension evidence:

• ▸Mice: 10–14% extension in median lifespan, even when initiated late in life (equivalent to humans starting at age 60) — replicated across multiple independent laboratories
• ▸Various model organisms: consistent lifespan extension across yeast, worms, flies, and mice
• ▸Dogs: Dog Aging Project's TRIAD trial investigating rapamycin in companion dogs — ongoing

Clinical status: The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) is investigating intermittent dosing schedules in healthy human adults to minimize the immunosuppressive side effects seen with continuous use (rapamycin is FDA-approved as an immunosuppressant for transplant patients). Results will inform whether the longevity benefit seen in animals translates to humans at tolerable doses.

The dose complexity: rapamycin at high continuous doses causes significant immunosuppression — the mechanism of its FDA-approved transplant use. At lower intermittent doses (e.g., once weekly), the immunosuppressive effects are substantially reduced while mTOR inhibition effects are maintained. Finding the therapeutic window for longevity benefit without immunosuppression is the key clinical challenge.

03. Metformin and the TAME Trial

Metformin — The Most Widely Used Geroprotector:

Metformin is an FDA-approved diabetes drug with a 60+ year safety record. Its anti-aging mechanism:

• ▸Primary: AMPK activation — stimulates energy-sensing pathways that overlap with caloric restriction signaling
• ▸Secondary: mild mitochondrial complex I inhibition, reducing oxidative stress
• ▸Tertiary effects: reducing systemic inflammation, improving glucose metabolism, potential gut microbiome effects

Epidemiological evidence: Diabetic patients on metformin have been observed in multiple large-scale studies to have lower all-cause mortality, lower cancer incidence, and lower cardiovascular event rates compared to diabetic patients on other medications — and in some analyses, lower event rates than non-diabetic individuals not on any diabetes medication. This "healthy user bias" is difficult to fully control for, but the signal has driven significant research interest.

The TAME Trial (Targeting Aging with Metformin):

The TAME trial is the first clinical trial explicitly targeting the aging process as its primary endpoint — not a specific disease.

• ▸Design: ~3,000 participants aged 65–79, randomized to metformin (1,500 mg/day) or placebo
• ▸Primary outcome: time to occurrence of the first of a composite of: cardiovascular events, cancer, dementia, death
• ▸Innovation: the composite outcome operationalizes "aging" as the accumulation of age-related conditions, providing a clinically measurable surrogate for biological aging rate
• ▸FDA significance: if TAME succeeds, it establishes a regulatory pathway for drugs targeting aging itself — a category that does not yet have an accepted clinical trial design framework
• ▸Status: ongoing; results expected over the coming years

The TAME regulatory significance extends beyond metformin: if the FDA accepts a composite aging outcome as a valid primary endpoint for drug approval, every longevity intervention becomes more clinically and regulatorily tractable. TAME is building the regulatory infrastructure for the longevity medicine field.

04. Senolytics — Clearing the Zombie Cells

Cellular senescence — Hallmark 8 — is the accumulation of cells that have stopped dividing but resist apoptosis (programmed cell death), remaining metabolically active and secreting a cocktail of pro-inflammatory cytokines, chemokines, and proteases collectively called the SASP (Senescence-Associated Secretory Phenotype).

Senescent cells accumulate with age in essentially every tissue. The SASP from accumulated senescent cells drives chronic inflammation, disrupts tissue function in adjacent healthy cells, and contributes to multiple age-related pathologies including fibrosis, osteoarthritis, cardiovascular disease, and neurodegeneration.

Senolytics — drugs that selectively eliminate senescent cells — are the therapeutic strategy targeting this hallmark:

The key evidence: animal studies with D+Q show dramatic effects — extending healthspan, reversing frailty, improving physical function, and extending lifespan in aged mice. The translation to humans is more complex: senescent cells serve protective roles (wound healing, tumor suppression) in addition to their harmful SASP function. Selectively eliminating harmful senescent cells without disrupting protective functions is the precision challenge.

05. The Major Companies and Capital Allocation

Rendering diagram...

Altos Labs — the landmark investment: Altos Labs was founded in 2021 with approximately $3 billion in committed funding — the largest single investment in longevity science history. Its scientific strategy centers on cellular reprogramming: using Yamanaka factors (the same transcription factors used to create induced pluripotent stem cells) to partially "reset" aged cells to a more youthful epigenetic state without fully dedifferentiating them. In animal experiments, partial reprogramming can reverse cellular aging markers and improve tissue function. Altos Labs is translating this into a human therapeutic program.

Calico (California Life Company) — the Google bet: Founded in 2013 with backing from Google/Alphabet and AbbVie, Calico has operated largely in research mode — publishing fundamental aging biology, building the scientific infrastructure to understand aging mechanisms, and developing drug candidates. The AbbVie partnership provides clinical development expertise. Calico has been criticized for slow translation to clinical programs relative to its capital commitment; the response is that the scientific questions required for longevity medicine are fundamentally harder than specific disease drug discovery.

06. The Biological Age Measurement Infrastructure

A critical enabling development for longevity medicine is the emergence of validated biological age clocks — measurements of how old your biology is, independent of your chronological age.

DNA methylation clocks:

• ▸Horvath Clock (2013): the first validated epigenetic aging clock, trained on methylation patterns across 353 CpG sites in the genome. Predicts biological age with ±3.6 year accuracy from tissue samples
• ▸Horvath Clock 2 / GrimAge: trained to predict not just biological age but time-to-mortality and age-related disease risk. GrimAge is the strongest predictor of mortality outcome among current clocks
• ▸DunedinPACE: trained to predict the pace of aging (years per chronological year) rather than biological age — measuring whether someone is aging faster or slower than their peers

Why these matter for longevity medicine: Clinical trials studying longevity interventions need a primary endpoint. "Has the patient lived longer?" requires decades of follow-up. Biological age clocks provide surrogate endpoints: "Has the patient's biological age been reduced (or slowed)?" measurable in years rather than decades.

The TRIIM-X trial (thymus regeneration) used the Horvath clock as a primary endpoint and observed reversal of biological age by ~2.5 years over 1 year of treatment — one of the first clinical trials reporting biological age reversal in humans.

07. The Regulatory and Scientific Frontier

The FDA and aging as a disease: The FDA does not currently classify aging itself as a disease. This creates a regulatory paradox: drugs targeting the aging process cannot receive approval for "aging" as an indication, only for specific age-related diseases (cardiovascular disease, diabetes, Alzheimer's). The TAME trial is attempting to create a composite "aging" endpoint that the FDA will accept — effectively constructing the regulatory framework for aging as an indication from the clinical trial design upward.

International regulatory divergence:

• ▸Japan has approved some longevity-adjacent interventions through expedited pathways for "prevention of lifestyle diseases"
• ▸Australia has been more permissive for investigational longevity drug protocols in clinical settings
• ▸The US has the most rigorous approval pathway but represents the largest market

The biomarker validation problem: The field suffers from a proliferation of "biological age" tests marketed directly to consumers — many with limited validation in independent cohorts. Distinguishing validated biomarker clocks (Horvath, GrimAge, DunedinPACE) from commercial tests with inadequate validation is critical for research integrity and clinical application.

08. The AI-Longevity Convergence

The intersection of AI drug discovery (Z3 dossier) and longevity science creates a particularly high-value research niche:

• ▸Multi-omics aging analysis: AI integration of genomics, epigenomics, proteomics, and metabolomics data to identify novel aging biomarkers and intervention targets — a problem of data complexity that is ideally suited to machine learning
• ▸Synergistic intervention discovery: aging is not driven by one mechanism but by 12 interacting hallmarks. AI can model the synergistic effects of combining interventions targeting different hallmarks — a complexity the human scientific mind struggles to track
• ▸Biological clock validation: training and validating methylation-based aging clocks requires large datasets and sophisticated ML — an area where AI drives the entire scientific measurement infrastructure
• ▸Drug repurposing for aging: existing drugs (like rapamycin and metformin) have been discovered as longevity candidates through observational data analysis. AI analysis of electronic health records, biobank data, and drug interaction databases is identifying additional repurposing candidates faster than traditional hypothesis-driven research

09. The Tresslers Group Thesis

Longevity science is not the pursuit of immortality. It is the engineering of healthspan — extending the years of vigorous, productive human life by targeting the biological processes that end it prematurely.

The scientific framework is now robust: 12 defined hallmarks with clear biological mechanisms, multiple intervention strategies with animal-level proof-of-concept, and the first human clinical trials accumulating evidence. The commercial infrastructure is building: Altos Labs, Calico, and a growing ecosystem of smaller companies translating science to clinical programs.

The remaining challenge is the same as in all early biomedical translation: the gap between compelling animal data and validated human clinical outcomes. Most interventions that extend mouse lifespan do not extend human lifespan for reasons that are biologically interesting and scientifically informative but commercially frustrating. The field is in the necessary period of clinical validation — building the evidence base that will eventually establish which interventions work in humans and which don't.

Zoirah monitors this evidence base continuously: tracking clinical trial results, biological clock validation studies, new company programs, and regulatory developments. The intelligence is synthesized for organizations investing in longevity science, deploying longevity-adjacent therapeutics, or making strategic decisions about the longevity medicine market.

The science is rigorous. The market is early. The intelligence gap is real.

References & Source Intelligence

1. ▸López-Otín, C. et al. (2023). "Hallmarks of Aging: An Expanding Universe." Cell, 186(2), 243-278.
2. ▸López-Otín, C. et al. (2013). "The Hallmarks of Aging." Cell, 153(6), 1194-1217.
3. ▸TAME Trial Consortium. (Ongoing). Targeting Aging with Metformin — ClinicalTrials.gov NCT04, ongoing.
4. ▸PEARL Trial. (Ongoing). Participatory Evaluation of Aging with Rapamycin for Longevity.
5. ▸Altos Labs. (2022). Company Founding Announcement — ~$3B Committed.
6. ▸Calico (Google/Alphabet). (2013–2025). Research publications and AbbVie partnership details.
7. ▸Unity Biotechnology. (2025). UBX1325 Phase II — Diabetic Macular Edema.
8. ▸Horvath, S. (2013). "DNA methylation age of human tissues and cell types." Genome Biology.
9. ▸Lu, A.T. et al. (2019). "DNA methylation GrimAge strongly predicts lifespan and healthspan." Aging.
10. ▸Tresslers Group Intelligence. (2026). Precision Medicine & Pharmacogenomics. [tresslersgroup.com/insights/precision-medicine-pharmacogenomics-2026]
11. ▸Tresslers Group Intelligence. (2026). AI Drug Discovery Pipeline. [tresslersgroup.com/insights/ai-drug-discovery-pipeline-2026]

Tresslers Group Intelligence — Zoirah Division Driven by Innovation. Defined by Impact. Scientific Intelligence at the Boundary of Human Lifespan. © 2026 Tresslers Group. Transmission Complete.